Abstract
The loss of early insulin secretion appears to be a critical event in the deterioration in glucose tolerance during the development of type 2 diabetes. There is therefore a strong rationale for developing new antidiabetic agents aimed at restoring or replacing early prandial insulin secretion and thereby curbing mealtime glucose excursions in patients with type 2 diabetes. Four such new agents are either now available (repaglinide and nateglinide) or in clinical development (KAD-1229 and BTS 67 582). Preclinical studies suggest that each of these new insulinotropic agents share a common receptor/effector mechanism with the sulfonylureas (SUs) but that each may have distinct characteristics that differentiate them from the SUs and from each other. Nateglinide and KAD-1229 clearly stimulate biphasic insulin secretion in vitro and in vivo and their effects are rapidly reversible, whereas the effects of repaglinide and BTS 67 582 are prolonged well beyond their removal from perfusion media in vitro or their clearance in vivo. Available data from human studies indicate that the pharmacokinetics of repaglinide and nateglinide are similar, i.e., they are both rapidly absorbed and eliminated, but consistent with findings from animal studies, the insulinotropic and glucose-lowering effects of repaglinide are slower in onset and more prolonged than those of nateglinide. Repaglinide and nateglinide have been shown to be safe and well-tolerated in patients with type 2 diabetes and to produce clinically-meaningful reductions of HbA1c, both alone and in combination with agents with complementary modes of action (e.g., metformin and thiazolidinediones). Because these new agents can potentially bring patients to near normoglycemia without an undue risk of hypoglycemia, they are important additions to the therapeutic armamentarium.
Keywords: Insulinotropic agents, type diabetes, igt, sulfonylurease, repaglinide, nateglinide, mitiglinide, nonsulfonylurea agents
Current Pharmaceutical Design
Title: Rapid Acting Insulinotropic Agents: Restoration of Early Insulin Secretion as a Physiologic Approach to Improve Glucose Control
Volume: 7 Issue: 14
Author(s): Richard E. Pratley, James E. Foley and Beth E. Dunning
Affiliation:
Keywords: Insulinotropic agents, type diabetes, igt, sulfonylurease, repaglinide, nateglinide, mitiglinide, nonsulfonylurea agents
Abstract: The loss of early insulin secretion appears to be a critical event in the deterioration in glucose tolerance during the development of type 2 diabetes. There is therefore a strong rationale for developing new antidiabetic agents aimed at restoring or replacing early prandial insulin secretion and thereby curbing mealtime glucose excursions in patients with type 2 diabetes. Four such new agents are either now available (repaglinide and nateglinide) or in clinical development (KAD-1229 and BTS 67 582). Preclinical studies suggest that each of these new insulinotropic agents share a common receptor/effector mechanism with the sulfonylureas (SUs) but that each may have distinct characteristics that differentiate them from the SUs and from each other. Nateglinide and KAD-1229 clearly stimulate biphasic insulin secretion in vitro and in vivo and their effects are rapidly reversible, whereas the effects of repaglinide and BTS 67 582 are prolonged well beyond their removal from perfusion media in vitro or their clearance in vivo. Available data from human studies indicate that the pharmacokinetics of repaglinide and nateglinide are similar, i.e., they are both rapidly absorbed and eliminated, but consistent with findings from animal studies, the insulinotropic and glucose-lowering effects of repaglinide are slower in onset and more prolonged than those of nateglinide. Repaglinide and nateglinide have been shown to be safe and well-tolerated in patients with type 2 diabetes and to produce clinically-meaningful reductions of HbA1c, both alone and in combination with agents with complementary modes of action (e.g., metformin and thiazolidinediones). Because these new agents can potentially bring patients to near normoglycemia without an undue risk of hypoglycemia, they are important additions to the therapeutic armamentarium.
Export Options
About this article
Cite this article as:
Pratley E. Richard, Foley E. James and Dunning E. Beth, Rapid Acting Insulinotropic Agents: Restoration of Early Insulin Secretion as a Physiologic Approach to Improve Glucose Control, Current Pharmaceutical Design 2001; 7 (14) . https://dx.doi.org/10.2174/1381612013397348
DOI https://dx.doi.org/10.2174/1381612013397348 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Health Care Discovery, Novo Nordisk A/S, DK-2880 Bagsværd, Denmark
Current Pharmaceutical Biotechnology Strategies for Non-Invasive Molecular Imaging of Acute Allograft Rejection by Gamma Scintigraphy and Positron Emission Tomography
Current Radiopharmaceuticals Emulsomes Meet S-layer Proteins: An Emerging Targeted Drug Delivery System
Current Pharmaceutical Biotechnology Oxidative Stress and Neurodegenerative Diseases: Looking for a Therapeutic Solution Inspired on Benzopyran Chemistry
Current Topics in Medicinal Chemistry Adverse Drug Reactions in a Pulmonary Teaching Hospital: Incidence, Pattern, Seriousness, and Preventability
Current Drug Safety Multiple Myeloma Bone Marrow Niche
Current Pharmaceutical Biotechnology TRPM Channels Phosphorylation as a Potential Bridge Between Old Signals and Novel Regulatory Mechanisms of Insulin Secretion
Current Diabetes Reviews Neurons vs. Germline: A War of Hormetic Tradeoffs
Current Aging Science Anti-hyperglycemic Potential of Natural Products
Mini-Reviews in Medicinal Chemistry Talking to the Synapse: How Antidepressants Can Target Glial Cells to Reshape Brain Circuits
Current Drug Targets <i>Delonix regia</i> a Folklore Remedy for Diabetes; Attenuates Oxidative Stress and Modulates Type II Diabetes Mellitus
Current Pharmaceutical Biotechnology Effects of Adding Large Doses of Arachidonic Acid to Docosahexaenoic Acid on Social Impairment in Individuals with Autism Spectrum Disorders
Current Psychopharmacology Stimuli-Responsive Molecularly Imprinted Polymers for Drug Delivery: A Review
Current Drug Delivery Recent Advancement of Polymersomes as Drug Delivery Carrier
Current Pharmaceutical Design Platelets as Potential Link Between Diabetes and Alzheimer's Disease
Current Alzheimer Research Posaconazole: A New Antifungal Weapon
Reviews on Recent Clinical Trials Sympathetic Activation in Congestive Heart Failure: Evidence, Consequences and Therapeutic Implications
Current Vascular Pharmacology MRI Abnormalities Associated with Mild Cognitive Impairments of Vascular (VMCI) Versus Neurodegenerative (NMCI) Types Prodromal for Vascular and Alzheimers Dementias
Current Alzheimer Research Reversal of Multidrug Resistance by Natural Substances from Plants
Current Topics in Medicinal Chemistry CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation